Glenn David - Zoetis Chief Financial Officer, Executive Vice President

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:3em;padding-top: 35px;;'>ZTS</div>
ZTS -- USA Stock  

Earning Report: February 13, 2020  

Mr. Glenn David serves as Chief Financial Officer and Executive Vice President of the Company. Mr. David has played a key role in leading the financial operations for Zoetis since its initial public offering in 2013. He served as our Senior Vice President of Finance Operations from 2013 to 2016 and as acting Chief Financial Officer from April 2014 through August 2014
Age: 46  President Since 2016      
973 822-7000
David joined Pfizer in 1999 and held various financial roles, including Vice President of Global Finance for Pfizer Animal Health, our predecessor company, and Vice President of Finance for the U.S. Primary Care franchise.

Glenn David Latest Insider Activity

Management Efficiency

The company has Return on Asset of 10.7 % which means that on every $100 spent on asset it made $10.7 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 0.01 % implying that it generated $0.01 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Reshma KewalramaniVertex Pharmaceuticals Incorpor
James MichaudPerrigo Company Plc
Thomas GraneyVertex Pharmaceuticals Incorpor
John HendricksonPerrigo Company Plc
Charles WagnerVertex Pharmaceuticals Incorpor
Amit SachdevVertex Pharmaceuticals Incorpor
Peter PowchikRegeneron Pharmaceuticals
Marion McCourtRegeneron Pharmaceuticals
Douglas BoothePerrigo Company Plc
John GrayVertex Pharmaceuticals Incorpor
Ganadhish KamatDr Reddys Laboratories Ltd
Michael AbermanRegeneron Pharmaceuticals
Paul SilvaVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd
Scott JamisonPerrigo Company Plc
Svend AndersenPerrigo Company Plc
J RamachandranDr Reddys Laboratories Ltd
George YancopoulosRegeneron Pharmaceuticals
Jay MarkowitzRegeneron Pharmaceuticals
Cartikeya ReddyDr Reddys Laboratories Ltd
Louis YuPerrigo Company Plc

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Return On Equity0.0052
Return On Asset10.70
Profit Margin23.81
Operating Margin39.29
Current Valuation66.13 B
Shares Outstanding476.3 M